Skip to main content
Clinical Trials/NCT05481814
NCT05481814
Withdrawn
Not Applicable

The Role of Cardiopulmonary Stress Testing in Diagnostic Evaluation of Paradoxical Low Gradient Aortic Valve Stenosis

Henry Ford Health System1 site in 1 countrySeptember 30, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Aortic Valve Stenosis
Sponsor
Henry Ford Health System
Locations
1
Primary Endpoint
Functional status
Status
Withdrawn
Last Updated
3 years ago

Overview

Brief Summary

Severe aortic stenosis is a condition with poor life expectancy once it becomes symptomatic. There are no prospective studies illustrating the utility of cardiopulmonary stress (CPX) testing in diagnosing and prognosticating patients with paradoxically low gradient and low flow severe aortic stenosis. We aim to prospectively investigate the utility of CPX in this patient population with the hypothesis that utilizing CPX parameters would better identify higher risk patients warranting further evaluation and possibly intervention sooner.

Detailed Description

This will be a prospective crossectional, longitudinal study recruiting patients by invitation with paradoxical low flow low gradient severe aortic stenosis. Patients with PLFLG AS will have been identified in other studies and these patients will be approached for enrollment in the study. Patients deemed appropriate for enrollment will undergo recumbent bicycle stress testing with concomitant measure of gas exchange. The bicycle will be at 30 degrees with initiation of minimal resistance for 3 minutes, followed by an increase in work-rate of 25 watts every two minutes until the patient reaches a sign/symptom-limited maximum exertion or test limiting symptoms develop. Charts will be reviewed for baseline medical conditions and demographics. CPX protocol will be standard HFH protocol supervised by exercise physiologist. The first phase of the study will be investigating if these asymptomatic patients will be reclassified to symptomatic as defined by reduced V02 Max. The second phase will be following these patients for long term adverse events and if V02 max correlates with a higher risk.

Registry
clinicaltrials.gov
Start Date
September 30, 2017
End Date
July 1, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Karthikeyan Ananthasubramaniam

Senior Staff Cardiologist

Henry Ford Health System

Eligibility Criteria

Inclusion Criteria

  • Aortic valve area \<1 cm2
  • Mean aortic pressure gradient \<40 mmHg,
  • Left ventricular ejection fraction \>50% by 2D transthoracic echocardiography

Exclusion Criteria

  • Ischemic heart disease
  • Severe mitral valve disease (regurgitation or stenosis)
  • Moderate or severe aortic regurgitation
  • Pulmonary hypertension (PA pressure \>50 mmHg)
  • Uncontrolled hypertension (Systolic BP or Diastolic BP greater than 150/90)
  • Inability or unwillingness to exercise.

Outcomes

Primary Outcomes

Functional status

Time Frame: August 30 2017-April 30 2017

Evaluate changes in rest vs. Peak V02 at maximal exercise capacity.

Secondary Outcomes

  • Follow-up(August 30 2017- August 30 2019)

Study Sites (1)

Loading locations...

Similar Trials